Holen Sie sich die Stockscreener-App
447.54
0.10%
-0.43
Handel nachbörslich:
447.54
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$447.97
Offen:
$448.01
24-Stunden-Volumen:
1.89M
Relative Volume:
1.46
Marktkapitalisierung:
$113.59B
Einnahmen:
$12.34B
Nettoeinkommen (Verlust:
$4.34B
KGV:
26.53
EPS:
16.8685
Netto-Cashflow:
$3.71B
1W Leistung:
+3.00%
1M Leistung:
+5.74%
6M Leistung:
+3.21%
1J Leistung:
+0.10%
1-Tages-Spanne:
$442.25
$450.00
1-Wochen-Bereich:
$433.79
$450.00
52-Wochen-Spanne:
$362.50
$507.92
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-03-10 | Bestätigt | Oppenheimer | Outperform |
| 2026-02-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Vertex Pharma stock (US92532F1003): Valuation stays in focus after a fresh move - AD HOC NEWS
VRTX: Renal franchise set to rival CF as new therapies and launches drive next phase of growth - TradingView
Vertex (VRTX) Announces Health Canada Acceptance of NDS for Suzetrigine - Insider Monkey
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals Inc stock (US92532F1003): Texas pension fund disclosure spotlights biotech he - AD HOC NEWS
These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth - Yahoo Finance
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - PR Newswire
Vertex’s Journavx made history, but left a void in the pain space - Pharma Voice
Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal - Fierce Pharma
Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs - TradingView
Ending the Pharma Relay Race with a Non-Opioid Breakthrough - PharmExec.com
Truist assumes Vertex stock coverage with buy rating on kidney drugs - Investing.com
Vertex Pharma stock (US92532F1003): cystic fibrosis franchise underpins valuation as investors weigh - AD HOC NEWS
Is Vertex Pharmaceuticals Successfully Diversifying Beyond Cystic Fibrosis - Kavout
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
Vertex Pharmaceuticals lays off 125 workers in RI - MSN
Vertex Pharma stock (US92532F1003): Health Canada review for new pain drug puts pipeline in focus - AD HOC NEWS
Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults - BioSpace
VRTX: Vertex Pharmaceuticals Seeks Approval for New Pain Treatme - GuruFocus
What Are Wall Street Analysts' Target Price for Vertex Pharmaceuticals Stock? - Yahoo Finance
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness - Yahoo Finance
VRTX Stock Price Prediction 2025-2026 | Vertex Pharmaceuticals Inc Forecast - 24/7 Wall St.
Vertex Pharmaceuticals Earnings Call Highlights New Growth Engines - TipRanks
Vertex Pharma stock (US92532F1003): cystic fibrosis leader eyes new growth drivers after latest pipe - AD HOC NEWS
META_TITLE_QUOTE - Yahoo Finance
Vertex Pharma stock (US92532F1003): cystic fibrosis leader eyes gene-editing future - AD HOC NEWS
Vertex Pharmaceuticals’ SWOT analysis: kidney drug stock draws mixed views - Investing.com Australia
J&J’s Duato makes 358 times his median employee; Vertex CEO makes just 80 times - BioSpace
Vertex Pharma stock (US92532F1003): insider selling puts focus on biotech heavyweight - AD HOC NEWS
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals Inc (VRTX) Stock Price, Trades & News - GuruFocus
Vertex Pharmaceuticals Insider Sold Shares Worth $613,971, According to a Recent SEC Filing - Moomoo
VRTX: CF and pipeline innovation drive growth, with JOURNAVX and Povi poised for major impact - TradingView
Vertex (VRTX) CSO Mark Bunnage sells 33 shares in pre-set 10b5-1 trade - Stock Titan
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharma stock (US92532F1003): cystic fibrosis leader after solid quarterly results - AD HOC NEWS
North Dakota State Investment Board Buys Shares of 8,821 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Canada Post Corp Registered Pension Plan Has $2.94 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock (US92532F1003): focus on cystic fibrosis and expanding pipeline - AD HOC NEWS
Vertex Pharma stock (US92532F1003): institutional flows and pipeline keep focus on biotech heavyweig - AD HOC NEWS
Vertex Pharmaceuticals stock (US92532F1003): gene-editing hopes meet kidney data buzz - AD HOC NEWS
Leuthold Group LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
STF Management LP Lowers Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (VX1.DE) Stock Price, News, Quote & History - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX.VI) Stock Price, News, Quote & History - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by DNB Asset Management AS - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Allworth Financial LP Has $6.36 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vertex Pharma stock (US92532F1003): Q1 numbers, ESOP shelf and gene-editing momentum draw investor f - AD HOC NEWS
Vertex Pharmaceuticals (NASDAQ: VRTX) insider files Form 144 to sell vested shares - Stock Titan
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
1.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):